See more : Hutech21 Co., Ltd. (CLGZF) Income Statement Analysis – Financial Results
Complete financial analysis of Genfit S.A. (GNFT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genfit S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ARB Holdings Limited (ARH.JO) Income Statement Analysis – Financial Results
- GuiZhou YongJi Printing CO.,LTD (603058.SS) Income Statement Analysis – Financial Results
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) Income Statement Analysis – Financial Results
- Waste Connections, Inc. (WCN) Income Statement Analysis – Financial Results
- Synopsys, Inc. (SYP.DE) Income Statement Analysis – Financial Results
Genfit S.A. (GNFT)
About Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.57M | 20.20M | 80.07M | 765.00K | 30.84M | 69.00K | 118.00K | 284.00K | 527.00K | 1.61M | 1.90M | 1.67M | 2.36M | 3.76M | 5.81M | 8.76M | 9.48M | 10.05M | 12.77M |
| Cost of Revenue | 341.00K | 248.00K | 161.00K | 202.00K | 177.00K | 1.85M | 2.23M | 1.99M | 1.93M | 1.40M | 1.29M | 1.20M | 1.41M | 1.37M | 1.61M | 1.74M | 2.01M | 1.69M | 1.32M |
| Gross Profit | 28.22M | 19.95M | 79.91M | 563.00K | 30.66M | -1.79M | -2.11M | -1.70M | -1.40M | 210.10K | 606.40K | 477.20K | 949.30K | 2.39M | 4.21M | 7.02M | 7.47M | 8.37M | 11.46M |
| Gross Profit Ratio | 98.81% | 98.77% | 99.80% | 73.59% | 99.43% | -2,586.96% | -1,788.98% | -598.94% | -266.41% | 13.01% | 31.93% | 28.54% | 40.21% | 63.57% | 72.37% | 80.10% | 78.84% | 83.23% | 89.68% |
| Research & Development | 46.71M | 35.82M | 35.17M | 59.10M | 66.17M | 47.66M | 35.10M | 19.19M | 5.39M | 9.02M | 5.16M | 4.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.04M | 16.41M | 16.15M | 14.27M | 17.27M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Selling & Marketing | 0.00 | 992.00K | 1.54M | 11.22M | 13.71M | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.04M | 17.40M | 17.69M | 25.49M | 30.97M | 13.63M | 13.41M | 11.66M | 9.13M | 9.37M | 7.38M | 6.45M | 6.02M | 6.91M | 0.00 | 0.00 | 6.20M | 4.81M | 4.71M |
| Other Expenses | 53.00K | -5.72M | -4.75M | -6.23M | -8.47M | 6.41M | 6.08M | 1.61M | 1.75M | 100.00 | -1.51M | -100.00 | 2.68M | 3.14M | 10.69M | 12.20M | 7.27M | 4.11M | 5.07M |
| Operating Expenses | 54.80M | 47.50M | 48.11M | 78.35M | 88.67M | 67.70M | 54.58M | 32.46M | 16.27M | 17.48M | 11.02M | 8.19M | 8.70M | 10.04M | 10.69M | 12.20M | 13.47M | 8.92M | 9.78M |
| Cost & Expenses | 55.15M | 47.50M | 48.11M | 78.35M | 88.67M | 69.55M | 56.81M | 34.44M | 18.20M | 18.88M | 12.32M | 9.39M | 10.11M | 11.41M | 12.29M | 13.94M | 15.47M | 10.61M | 11.10M |
| Interest Income | 1.71M | 8.21M | 44.78M | 6.54M | 5.22M | 202.00K | 389.00K | 316.00K | 437.00K | 329.00K | 169.20K | 201.40K | 322.80K | 205.70K | 300.90K | 596.00K | 768.90K | 399.70K | 53.40K |
| Interest Expense | 4.62M | 4.76M | 7.12M | 25.30M | 13.11M | 10.98M | 1.39M | 110.00K | 0.00 | 93.70K | 103.10K | 238.40K | 372.80K | 391.40K | 449.10K | 205.20K | 390.80K | 308.80K | 332.90K |
| Depreciation & Amortization | 1.65M | 1.83M | 2.74M | 4.75M | 5.25M | 1.44M | 1.53M | 799.00K | 327.00K | 292.10K | 465.50K | 556.30K | 788.80K | 919.60K | 1.06M | 1.00M | 943.90K | 537.70K | 874.40K |
| EBITDA | -22.24M | -23.60M | 34.91M | -91.14M | -51.02M | -68.08M | -55.76M | -33.53M | -17.35M | -16.98M | -9.95M | -6.77M | -6.64M | -6.53M | -5.09M | -3.41M | -4.07M | 930.30K | 2.60M |
| EBITDA Ratio | -77.84% | -85.45% | 99.26% | -8,821.70% | -153.07% | -97,182.61% | -46,264.41% | -11,550.70% | -3,146.30% | -1,029.08% | -509.17% | -405.08% | -281.18% | -173.79% | -88.67% | -40.07% | -43.19% | 1.16% | 20.38% |
| Operating Income | -26.58M | -27.55M | 76.74M | -77.79M | -57.83M | -69.48M | -56.70M | -34.16M | -17.68M | -17.26M | -10.51M | -7.72M | -7.75M | -7.66M | -6.47M | -5.17M | -5.99M | -553.30K | 1.68M |
| Operating Income Ratio | -93.05% | -136.41% | 95.84% | -10,168.76% | -187.53% | -100,701.45% | -48,046.61% | -12,027.46% | -3,354.08% | -1,069.04% | -553.56% | -461.39% | -328.32% | -203.82% | -111.40% | -59.06% | -63.21% | -5.50% | 13.12% |
| Total Other Income/Expenses | -1.93M | 3.45M | -7.26M | -18.75M | -7.89M | -10.39M | -2.45M | 526.00K | 541.00K | 234.00K | 179.60K | -13.60K | -50.00K | -185.70K | -177.50K | 559.20K | 611.00K | 223.60K | 33.40K |
| Income Before Tax | -28.51M | -23.84M | 69.47M | -101.65M | -65.72M | -79.88M | -58.22M | -33.63M | -17.14M | -17.03M | -10.33M | -7.73M | -7.80M | -7.84M | -6.65M | -4.71M | -5.38M | -329.70K | 1.71M |
| Income Before Tax Ratio | -99.82% | -118.03% | 86.77% | -13,287.45% | -213.11% | -115,760.87% | -49,338.14% | -11,841.55% | -3,251.42% | -1,054.57% | -544.10% | -462.21% | -330.44% | -208.76% | -114.46% | -53.79% | -56.76% | -3.28% | 13.38% |
| Income Tax Expense | 380.00K | -116.00K | 2.22M | -428.00K | -576.00K | -354.00K | 384.00K | 35.00K | 227.00K | 400.00 | 2.32M | -2.32M | 1.88M | 1.54M | 721.50K | -751.40K | -2.58M | -665.40K | 74.40K |
| Net Income | -28.89M | -23.72M | 67.26M | -101.22M | -65.15M | -79.52M | -58.60M | -33.67M | -17.14M | -17.03M | -12.65M | -5.41M | -9.68M | -9.38M | -7.37M | -3.96M | -2.80M | 327.70K | 1.77M |
| Net Income Ratio | -101.15% | -117.45% | 84.00% | -13,231.50% | -211.24% | -115,247.83% | -49,664.41% | -11,854.58% | -3,251.42% | -1,054.60% | -666.15% | -323.60% | -410.09% | -249.65% | -126.87% | -45.21% | -29.55% | 3.26% | 13.88% |
| EPS | -0.58 | -0.48 | 1.50 | -2.60 | -1.76 | -2.55 | -1.88 | -1.28 | -0.69 | -0.76 | -0.65 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| EPS Diluted | -0.58 | -0.48 | 1.21 | -2.60 | -1.76 | -2.55 | -1.88 | -1.25 | -0.69 | -0.74 | -0.63 | -0.35 | -0.75 | -0.78 | -0.63 | -0.34 | -0.24 | 0.03 | 0.15 |
| Weighted Avg Shares Out | 49.70M | 49.67M | 44.74M | 38.86M | 36.99M | 31.17M | 31.16M | 26.35M | 24.70M | 22.29M | 19.41M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
| Weighted Avg Shares Out (Dil) | 49.70M | 49.67M | 55.61M | 38.86M | 36.99M | 31.17M | 31.17M | 26.85M | 24.70M | 22.98M | 20.01M | 15.32M | 12.88M | 11.97M | 11.62M | 11.62M | 11.62M | 11.62M | 11.62M |
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead...
GENFIT Reports Third Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as...
Top 4 Health Care Stocks That May Keep You Up At Night
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission...
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of...
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+®...
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 10, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the achievement of a...
US FDA approves Genfit and Ipsen's liver disease drug
The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory liver disease, Ipsen said on Monday.
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the...
Source: https://incomestatements.info
Category: Stock Reports